abmart-banner
Global R&D Pipeline
My Favorite
Hot Targets:
Home>AbMart>

Global R&D Pipeline

ENPP3
Back
Total number of drugs
13
Phase II and later clinical stages
7.7%
Involving companies
14
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
DrugDrug Name EnDrug TypeTreatment FieldMechanism of ActionOriginatorDeveloperIndicationHighest Development StageHighest Development Stage (China)Approved Countries/RegionsApproved TimeApproved Time (China)Special ReviewADC TypeADC LinkerADC PayloadADC DARDrug NameAntibody TypeADC Linking SiteOperation
JNJ-89862175JNJ-89862175Antibody drug conjugate (ADC) ADCNeoplasmsEctonucleotide pyrophosphatase/phosphodiesterase family member 3 inhibitorsJanssen Research & Development LLCJanssen Research & Development LLCPhase 1AuristatinJNJ-89862175
detail  >
Compound 3e(Bahauddin Zakariya University)Compound 3e(Bahauddin Zakariya University)Small molecule drugNeoplasmsEctonucleotide pyrophosphatase/phosphodiesterase family member 3 inhibitorsBahauddin Zakariya UniversityBahauddin Zakariya UniversityPreclinicalCompound 3e(Bahauddin Zakariya University)
detail  >
ENPP3-targeted prodrug TCE(Probio)ENPP3-targeted prodrug TCE(Probio)Bispecific T-cell Engager (BiTE)Neoplasms Hemic and Lymphatic DiseasesT cell surface glycoprotein CD3 stimulants Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 inhibitorsJiangsu GenScript Probio Biotech Co., Ltd.Jiangsu GenScript Probio Biotech Co., Ltd.PreclinicalPreclinicalENPP3-targeted prodrug TCE(Probio)
detail  >
ENPP3/CD3 Bispecific antibody(Jinsirui Vigorous)ENPP3/CD3 Bispecific antibody(Jinsirui Vigorous)Bispecific antibodyT cell surface glycoprotein CD3 stimulants Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 inhibitorsShanghai Jinsirui Vigorous Biotechnology Co., Ltd.Shanghai Jinsirui Vigorous Biotechnology Co., Ltd.PreclinicalPreclinicalENPP3/CD3 Bispecific antibody(Jinsirui Vigorous)
detail  >
SIM0680SIM0680Antibody drug conjugate (ADC) ADCNeoplasmsEctonucleotide pyrophosphatase/phosphodiesterase family member 3 inhibitorsSimcere Pharmaceutical Group Ltd.Simcere Pharmaceutical Group Ltd.PreclinicalPreclinicalSIM0680
detail  >
CN122464909CN122464909Small molecule drugNeoplasmsXi'an Jiaotong UniversityXi'an Jiaotong UniversityDiscoveryCN122464909
detail  >
CN122608499CN122608499Small molecule drugNeoplasms Other DiseasesBeijing Dr. Plant Biotechnology Co., Ltd.Dr. Plant(Guangdong)Biotechnology Co. Ltd.Beijing Dr. Plant Biotechnology Co., Ltd.DiscoveryCN122608499
detail  >
JP2024032952JP2024032952Recombinant polypeptideEndocrinology and Metabolic Disease Other DiseasesYale UniversityYale UniversityDiscoveryJP2024032952
detail  >
WO2025240361WO2025240361Small molecule drugNeoplasmsEctonucleotide pyrophosphatase/phosphodiesterase family member 1 inhibitors Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 inhibitorsBoard of Trustees of the Leland Stanford Junior UniversityBoard of Trustees of the Leland Stanford Junior UniversityDiscoveryWO2025240361
detail  >
AGS-16M18AGS-16M18Monoclonal antibodyNeoplasms Urogenital DiseasesEctonucleotide pyrophosphatase/phosphodiesterase family member 3 inhibitorsAstellas Pharma, Inc.Phase 1AGS-16M18
detail  >
Total 13 data
1
2